These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24872363)

  • 1. The utility of Bayesian predictive probabilities for interim monitoring of clinical trials.
    Saville BR; Connor JT; Ayers GD; Alvarez J
    Clin Trials; 2014 Aug; 11(4):485-493. PubMed ID: 24872363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian Sequential Monitoring of Single-Arm Trials: A Comparison of Futility Rules Based on Binary Data.
    Sambucini V
    Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive probability methods for interim monitoring in clinical trials with longitudinal outcomes.
    Zhou M; Tang Q; Lang L; Xing J; Tatsuoka K
    Stat Med; 2018 Jun; 37(14):2187-2207. PubMed ID: 29664214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
    Ryan EG; Brock K; Gates S; Slade D
    BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian predictive approach to interim monitoring in clinical trials.
    Dmitrienko A; Wang MD
    Stat Med; 2006 Jul; 25(13):2178-95. PubMed ID: 16007570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal timing for an accelerated interim futility analysis incorporating real world data.
    Haine LMF; Murray TA; Koopmeiners JS
    Contemp Clin Trials; 2024 May; 140():107489. PubMed ID: 38461938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions-A calibration approach.
    Kopp-Schneider A; Wiesenfarth M; Witt R; Edelmann D; Witt O; Abel U
    Biom J; 2019 May; 61(3):488-502. PubMed ID: 30175405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian Interim Analysis and Efficiency of Phase III Randomized Trials.
    Sherry AD; Msaouel P; Miller AM; Lin TA; Kupferman GS; Jaoude JA; Kouzy R; El-Alam MB; Patel R; Koong A; Lin C; Meirson T; McCaw ZR; Ludmir EB
    medRxiv; 2024 Jun; ():. PubMed ID: 38978666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic survey of randomised trials that stopped early for reasons of futility.
    Walter SD; Han H; Guyatt GH; Bassler D; Bhatnagar N; Gloy V; Schandelmaier S; Briel M
    BMC Med Res Methodol; 2020 Jan; 20(1):10. PubMed ID: 31948397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A flexible futility monitoring method with time-varying conditional power boundary.
    Ying Zhang ; Clarke WR
    Clin Trials; 2010 Jun; 7(3):209-18. PubMed ID: 20423927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Bayesian and frequentist monitoring boundaries motivated by the Multiplatform Randomized Clinical Trial.
    Joo J; Leifer ES; Proschan MA; Troendle JF; Reynolds HR; Hade EA; Lawler PR; Kim DY; Geller NL
    Clin Trials; 2024 May; ():17407745241244801. PubMed ID: 38760932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial.
    Chen DT; Schell MJ; Fulp WJ; Pettersson F; Kim S; Gray JE; Haura EB
    Transl Cancer Res; 2019 Jul; 8(Suppl 4):S404-S420. PubMed ID: 31456910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epistemic uncertainty in Bayesian predictive probabilities.
    Liu CC; Yu RX
    J Biopharm Stat; 2024 May; 34(3):394-412. PubMed ID: 37157818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining a Bayesian predictive power stopping rule for futility in a non-inferiority trial with binary outcomes.
    Heath A; Offringa M; Pechlivanoglou P; Rios JD; Klassen TP; Poonai N; Pullenayegum E;
    Contemp Clin Trials Commun; 2020 Jun; 18():100561. PubMed ID: 32300671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian predictive probabilities: a good way to monitor clinical trials.
    Ferreira D; Ludes PO; Diemunsch P; Noll E; Torp KD; Meyer N
    Br J Anaesth; 2021 Feb; 126(2):550-555. PubMed ID: 33129491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advantages of Bayesian monitoring methods in deciding whether and when to stop a clinical trial: an example of a neonatal cooling trial.
    Pedroza C; Tyson JE; Das A; Laptook A; Bell EF; Shankaran S;
    Trials; 2016 Jul; 17(1):335. PubMed ID: 27450203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian noninferiority test for 2 binomial probabilities as the extension of Fisher exact test.
    Doi M; Takahashi F; Kawasaki Y
    Stat Med; 2017 Dec; 36(30):4789-4803. PubMed ID: 28960376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.